Compare Stocks → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AMYTCVE:BMKNYSEARCA:EPINASDAQ:FIRETSE:HLS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsBMKMacDonald Mines ExplorationC$0.04-12.5%C$0.05C$0.03▼C$0.09C$1.33M0.475,091 shs2,000 shsEPIWisdomTree India Earnings Fund$44.59+0.3%$43.84$32.15▼$45.02$2.96B0.561.08 million shs1.06 million shsFIRE(FIRE)$0.00$0.00▼$0.00N/AN/AN/AN/AHLSHLS TherapeuticsC$4.75C$4.26C$3.34▼C$7.12C$151.62M1.169,650 shs2,000 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%BMKMacDonald Mines Exploration0.00%-12.50%-22.22%-22.22%-36.36%EPIWisdomTree India Earnings Fund+0.29%+1.55%+4.52%+6.83%+37.92%FIRE(FIRE)0.00%0.00%0.00%0.00%0.00%HLSHLS Therapeutics0.00%-2.86%+23.70%+16.42%-20.83%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AN/AN/AN/AN/AEPIWisdomTree India Earnings FundN/AN/AN/AN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AN/AN/AN/AHLSHLS Therapeutics0.0571 of 5 stars1.10.01.70.00.60.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt PharmaN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AEPIWisdomTree India Earnings Fund0.00N/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AHLSHLS Therapeutics2.25HoldC$4.58-3.68% DownsideCurrent Analyst RatingsLatest BMK, AMYT, HLS, FIRE, and EPI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2024HLSHLS TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$6.50 ➝ C$5.003/15/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$4.35 ➝ C$4.152/22/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$5.00 ➝ C$4.352/6/2024HLSHLS TherapeuticsClarus SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63BMKMacDonald Mines ExplorationC$-74K-17.92C$0.00 per share13.00C($0.01) per share-3.50EPIWisdomTree India Earnings FundN/AN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$63.07M2.40C$0.31 per share15.22C$3.06 per share1.55Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/ABMKMacDonald Mines Exploration-C$1.28M-C$0.02N/A∞N/AN/A-1,679.48%-324.12%6/4/2024 (Estimated)EPIWisdomTree India Earnings FundN/AN/A15.51∞N/AN/AN/AN/AN/AFIRE(FIRE)N/AN/A0.00N/AN/AN/AN/AN/AN/AHLSHLS Therapeutics-C$27.53M-C$1.16N/A∞N/A-43.65%-24.69%-2.87%5/9/2024 (Estimated)Latest BMK, AMYT, HLS, FIRE, and EPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023HLSHLS Therapeutics-C$0.13-C$0.18-C$0.05-C$0.13C$21.83 millionC$21.60 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AN/AEPIWisdomTree India Earnings Fund$1.964.40%N/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.21%N/AN/A N/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94BMKMacDonald Mines Exploration3.840.220.27EPIWisdomTree India Earnings FundN/AN/AN/AFIRE(FIRE)N/AN/AN/AHLSHLS Therapeutics89.691.651.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%BMKMacDonald Mines Exploration1.10%EPIWisdomTree India Earnings FundN/AFIRE(FIRE)N/AHLSHLS Therapeutics59.62%Insider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%BMKMacDonald Mines Exploration7.58%EPIWisdomTree India Earnings FundN/AFIRE(FIRE)N/AHLSHLS Therapeutics0.49%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableBMKMacDonald Mines Exploration237.88 millionN/ANot OptionableEPIWisdomTree India Earnings FundN/A66.40 millionN/ANot OptionableFIRE(FIRE)N/AN/AN/ANot OptionableHLSHLS Therapeutics9131.92 millionN/ANot OptionableBMK, AMYT, HLS, FIRE, and EPI HeadlinesSourceHeadlineBranching Regulatory Paths and Dead Ends in Psychedelicstheregreview.org - April 15 at 1:53 AMWho Is Cara Mund? Former Miss America Who Supports Abortion Rights Announces Run for US House as Republican in North Dakotaibtimes.sg - April 10 at 12:16 AMHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferencefinance.yahoo.com - April 9 at 8:27 AMCara Mund running for US House in North Dakota Republican primarybismarcktribune.com - April 8 at 5:55 PMNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroupsfinance.yahoo.com - April 8 at 7:31 AMGetting to Yes, And…| Elaine Lin Hering – Unlearning Silencewgnradio.com - April 2 at 10:55 AMEarnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57finance.yahoo.com - March 17 at 10:03 AMHLS has price target cut at Raymond Jamescantechletter.com - March 15 at 8:14 PMHLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%finance.yahoo.com - March 14 at 12:41 PMHLS Therapeutics Announces Fiscal 2023 Financial Resultsfinance.yahoo.com - March 14 at 7:34 AMHLS Therapeutics earnings: here's what to expectmarkets.businessinsider.com - March 13 at 10:32 AMAmicus Curiae Returning to Campusmarshallparthenon.com - February 21 at 1:11 PMSeveral Insiders Invested In HLS Therapeutics Flagging Positive Newsfinance.yahoo.com - February 21 at 1:11 PMStocks in play: HLS Therapeutics Inc.ca.finance.yahoo.com - February 6 at 1:07 PMHLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Planfinance.yahoo.com - February 6 at 7:35 AMJennifer J. Raab named President and CEO of The New York Stem Cell Foundationeurekalert.org - January 31 at 10:48 PMPharma breakthroughs: 10 novel drug approvals that made headlines in 2023msn.com - December 20 at 11:16 AMHLS Therapeutics CFO Tim Hendrickson to Step Downmarketwatch.com - December 18 at 7:58 AMHLS Therapeutics appoints John Hanna as interim CFOmsn.com - December 18 at 7:58 AMHLS Therapeutics Announces CFO Departurefinance.yahoo.com - December 18 at 7:58 AM2 Top Pharmaceutical Stocks to Buy on the TSX Todaymsn.com - December 11 at 7:41 PMCerebral venous thrombosis should be considered in a postpartum patient with headache and seizurecmaj.ca - December 11 at 9:41 AMSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimatesfinance.yahoo.com - November 15 at 7:05 AMNew REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baselinefinance.yahoo.com - November 14 at 5:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsMissed Taiwan Semi’s Rise? Try United Microelectronics April 17, 2024 7:00 AMView Missed Taiwan Semi’s Rise? Try United Microelectronics All Headlines Company DescriptionsAmryt PharmaNASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.MacDonald Mines ExplorationCVE:BMKMacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interest in the Scadding-Powerline-Jovan property that covers an area of 19,710 hectares located to the east of Sudbury in Northern Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was incorporated in 1936 and is based in Toronto, Canada.WisdomTree India Earnings FundNYSEARCA:EPIWisdomTree India Earnings Fund (The Fund) seeks to track the price and yield performance, before fees and expenses, of the WisdomTree India Earnings Index. The Index measures the performance of profitable companies incorporated and traded in India that are eligible to be purchased by foreign investors and that meet specific criteria developed by WisdomTree Investments.(FIRE)NASDAQ:FIRESourcefire, Inc. (Sourcefire) is engaged in the business of delivering intelligent cybersecurity technologies. The Company provides a portfolio of solutions that enables commercial enterprises and government agencies worldwide to manage and minimize cybersecurity risks. Sourcefire provides customers with Agile Security that consists of hardware with embedded software, software and cloud-based solutions. It sells its solutions to a customer base that includes Global 2000 companies, global enterprises, the United States and international government agencies, and small and mid-size businesses. During the year ended December 31, 2012, it generated approximately 67% of the Company's revenue from customers in the United States, and 33% of the Company's revenue from customers outside of the United States. As of December 31, 2012, its product revenue and services revenue represented 61% and 39% of its total revenue, respectively.HLS TherapeuticsTSE:HLSHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.